-
1
-
-
24344503816
-
HCV natural history: The retrospective and prospective in perspective
-
Alter HJ: HCV natural history: the retrospective and prospective in perspective. J Hepatol 2005; 43: 550-52
-
(2005)
J Hepatol
, vol.43
, pp. 550-552
-
-
Alter, H.J.1
-
2
-
-
70350614356
-
Pegylated IFN-a2a and ribavirin in the treatment of hepatitis C
-
Aghemo A, Rumi MG, Colombo M: Pegylated IFN-a2a and ribavirin in the treatment of hepatitis C. Expert Rev Anti Infect Ther 2009; 7: 925-35
-
(2009)
Expert Rev Anti Infect Ther
, vol.7
, pp. 925-935
-
-
Aghemo, A.1
Rumi, M.G.2
Colombo, M.3
-
3
-
-
79751494192
-
Virologic response to treatment with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C in children
-
Pawlowska M, Pilarczyk M, Halota W: Virologic response to treatment with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C in children. Med Sci Monit 2010; 16(12): CR616-21
-
(2010)
Med Sci Monit
, vol.16
, Issue.12
-
-
Pawlowska, M.1
Pilarczyk, M.2
Halota, W.3
-
4
-
-
24944552848
-
Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan
-
Kumada T, Toyoda H, Honda T et al: Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan. Intervirology 2006; 49: 112-18
-
(2006)
Intervirology
, vol.49
, pp. 112-118
-
-
Kumada, T.1
Toyoda, H.2
Honda, T.3
-
5
-
-
0036830199
-
Retreatment of patients with chronic hepatitis C
-
Shiffman ML: Retreatment of patients with chronic hepatitis C. Hepatology 2002; 36: S128-34
-
(2002)
Hepatology
, vol.36
-
-
Shiffman, M.L.1
-
6
-
-
34547428001
-
Prediction of response of US veterans to treatment for the hepatitis C virus
-
Backus LI, Boothroyd DB, Phillips BR, Mole LA: Prediction of response of US veterans to treatment for the hepatitis C virus. Hepatology, 2007; 46: 37-47
-
(2007)
Hepatology
, vol.46
, pp. 37-47
-
-
Backus, L.I.1
Boothroyd, D.B.2
Phillips, B.R.3
Mole, L.A.4
-
7
-
-
37749030473
-
Predictions of treatment in patients with chronic hepatitis C infection-role of patient versus nonpatient factors
-
Kanwal F, Hoang T, Spiegel BM et al: Predictions of treatment in patients with chronic hepatitis C infection-role of patient versus nonpatient factors. Hepatology, 2007; 46: 1741-49
-
(2007)
Hepatology
, vol.46
, pp. 1741-1749
-
-
Kanwal, F.1
Hoang, T.2
Spiegel, B.M.3
-
8
-
-
77953553818
-
Hyperinsulinemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance
-
Bortoletto G, Scribano L, Realdon S et al: Hyperinsulinemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. J Viral Hepat, 2010; 17: 475-80
-
(2010)
J Viral Hepat
, vol.17
, pp. 475-480
-
-
Bortoletto, G.1
Scribano, L.2
Realdon, S.3
-
9
-
-
0032475822
-
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy
-
Neumann AU, Lam NP, Dahari H et al: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science, 1998; 282: 103-7
-
(1998)
Science
, vol.282
, pp. 103-107
-
-
Neumann, A.U.1
Lam, N.P.2
Dahari, H.3
-
10
-
-
0031009603
-
Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon a
-
Lam NP, Neumann AU, Gretch DR et al: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon a. Hepatology, 1997; 26: 226-31
-
(1997)
Hepatology
, vol.26
, pp. 226-231
-
-
Lam, N.P.1
Neumann, A.U.2
Gretch, D.R.3
-
11
-
-
0032102892
-
Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy
-
Bekkering FC, Brouwer JT, Leroux-Roels G et al: Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol, 1998; 28: 960-64
-
(1998)
J Hepatol
, vol.28
, pp. 960-964
-
-
Bekkering, F.C.1
Brouwer, J.T.2
Leroux-Roels, G.3
-
12
-
-
0035050182
-
Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon a2a
-
Zeuzem S, Herrmann E, Lee JH et al: Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon a2a. Gastroenterology, 2001; 120: 1438-47
-
(2001)
Gastroenterology
, vol.120
, pp. 1438-1447
-
-
Zeuzem, S.1
Herrmann, E.2
Lee, J.H.3
-
13
-
-
0036208536
-
Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon a-2b plus ribavirin
-
Buti M, Sanchez-Avila F, Lurie Y et al: Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon a-2b plus ribavirin. Hepatology, 2002; 35: 930-36
-
(2002)
Hepatology
, vol.35
, pp. 930-936
-
-
Buti, M.1
Sanchez-Avila, F.2
Lurie, Y.3
-
14
-
-
78649251945
-
A perspective on modeling hepatitis C virus infection
-
Guedj J, Rong L, Dahari H, Perelson AS: A perspective on modeling hepatitis C virus infection. J Viral Hepat, 2010; 17: 825-53
-
(2010)
J Viral Hepat
, vol.17
, pp. 825-853
-
-
Guedj, J.1
Rong, L.2
Dahari, H.3
Perelson, A.S.4
-
15
-
-
56749177311
-
A hepatitis C viral kinetic model that allows for time-varying drug effectiveness
-
Shudo E, Riberio RM, Talal AH, Perelson AS: A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir Ther, 2008; 13: 919-26
-
(2008)
Antivir Ther
, vol.13
, pp. 919-926
-
-
Shudo, E.1
Riberio, R.M.2
Talal, A.H.3
Perelson, A.S.4
-
16
-
-
41549108436
-
Modeling hepatitis C virus kinetics during treatment with pegylated interferon a-2b: Errors in the estimation of viral kinetic parameters
-
Shudo E, Riberio RM, Perelson AS: Modeling hepatitis C virus kinetics during treatment with pegylated interferon a-2b: errors in the estimation of viral kinetic parameters. J Viral Hepat, 2008; 15: 357-62
-
(2008)
J Viral Hepat
, vol.15
, pp. 357-362
-
-
Shudo, E.1
Riberio, R.M.2
Perelson, A.S.3
-
17
-
-
49149090985
-
Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells
-
Colombatto P, Ciccorossi P, Maina AM et al: Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells. Clin Pharmacol Ther, 2008; 84: 212-15
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 212-215
-
-
Colombatto, P.1
Ciccorossi, P.2
Maina, A.M.3
-
18
-
-
33749237156
-
First phase viral kinetic parameters and prediction of response to interferon a-2b/ribavirin combination therapy in patients with chronic hepatitis C
-
Makiyama A, Itoh Y, Yasui K et al: First phase viral kinetic parameters and prediction of response to interferon a-2b/ribavirin combination therapy in patients with chronic hepatitis C. Hepatol Res, 2006; 36: 94-99
-
(2006)
Hepatol Res
, vol.36
, pp. 94-99
-
-
Makiyama, A.1
Itoh, Y.2
Yasui, K.3
-
19
-
-
64549090121
-
Viral kinetic of HCV genotype-4 during pegylated interferon a 2a: Ribavirin therapy
-
Derbala MF, El Dweik NZ, Al Kaabi SR et al: Viral kinetic of HCV genotype-4 during pegylated interferon a 2a: ribavirin therapy. J Viral Hepat, 2008; 15: 591-99
-
(2008)
J Viral Hepat
, vol.15
, pp. 591-599
-
-
Derbala, M.F.1
El Dweik, N.Z.2
Al Kaabi, S.R.3
-
20
-
-
75349106114
-
Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b
-
Sasase N, Kim SR, Kudo M et al: Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b. Intervirology, 2010; 53: 49-54
-
(2010)
Intervirology
, vol.53
, pp. 49-54
-
-
Sasase, N.1
Kim, S.R.2
Kudo, M.3
-
21
-
-
67650132966
-
Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin
-
Elefsiniotis IS, Vezali E, Mihas C, Saroglou G: Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Intervirology, 2009; 52: 247-51
-
(2009)
Intervirology
, vol.52
, pp. 247-251
-
-
Elefsiniotis, I.S.1
Vezali, E.2
Mihas, C.3
Saroglou, G.4
-
22
-
-
68249154875
-
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
-
McHutchison JG, Lawitz EJ, Shiffman ML et al: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. New Engl J Med, 2009; 361: 580-93
-
(2009)
New Engl J Med
, vol.361
, pp. 580-593
-
-
McHutchison, J.G.1
Lawitz, E.J.2
Shiffman, M.L.3
-
23
-
-
44849097562
-
Scientific rationale and study design of the individualized dosing efficacy vs. flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: Determining optimal dosing in patients with genotype 1 chronic hepatitis C
-
McHutchison JG, Sulkowski M: Scientific rationale and study design of the individualized dosing efficacy vs. flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat, 2008; 15: 475-81
-
(2008)
J Viral Hepat
, vol.15
, pp. 475-481
-
-
McHutchison, J.G.1
Sulkowski, M.2
-
24
-
-
73149116017
-
Pharmacotherapy of chronic hepatitis C virus infection-the IDEAL trial: '2b or not 2b (=2a), that is the question'
-
Toyoda H, Kumada T: Pharmacotherapy of chronic hepatitis C virus infection-the IDEAL trial: '2b or not 2b (=2a), that is the question'. Expert Opin Pharmacother, 2009; 10: 2845-57
-
(2009)
Expert Opin Pharmacother
, vol.10
, pp. 2845-2857
-
-
Toyoda, H.1
Kumada, T.2
-
25
-
-
33746239302
-
Viral kinetics in the treatment of chronic hepatitis C
-
Layden-Almer JE, Cotler SJ, Layden TJ: Viral kinetics in the treatment of chronic hepatitis C. J Hepatol, 2006; 13: 499-504
-
(2006)
J Hepatol
, vol.13
, pp. 499-504
-
-
Layden-Almer, J.E.1
Cotler, S.J.2
Layden, T.J.3
-
26
-
-
0041317672
-
Viral kinetics in hepatitis C virus: Special patients populations
-
Layden-Almer JE, Layden TJ: Viral kinetics in hepatitis C virus: special patients populations. Semin Liver Dis, 2003; 23(Suppl.1): 29-33
-
(2003)
Semin Liver Dis
, vol.23
, Issue.SUPPL. 1
, pp. 29-33
-
-
Layden-Almer, J.E.1
Layden, T.J.2
-
27
-
-
0038820380
-
Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin
-
Layden-Almer JE, Ribeiro RM, Wiley T et al: Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology, 2003; 37: 1343-50
-
(2003)
Hepatology
, vol.37
, pp. 1343-1350
-
-
Layden-Almer, J.E.1
Ribeiro, R.M.2
Wiley, T.3
-
28
-
-
82755192524
-
Association between amino acids 70 and 91 in the HCV core region and second-phase viral decline during antiviral therapy for patients with HCV 1b
-
Nakao R, Yatsuhashi H, Hashimoto S et al: Association between amino acids 70 and 91 in the HCV core region and second-phase viral decline during antiviral therapy for patients with HCV 1b. J Hepatol, 2009; 50; S234
-
(2009)
J Hepatol
, vol.50
-
-
Nakao, R.1
Yatsuhashi, H.2
Hashimoto, S.3
-
29
-
-
20644441571
-
Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
-
Bodenheimer HC Jr, Lindsay KI, Davis GL et al: Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology, 1997; 26: 473-77
-
(1997)
Hepatology
, vol.26
, pp. 473-477
-
-
Bodenheimer Jr., H.C.1
Lindsay, K.I.2
Davis, G.L.3
-
30
-
-
0031831349
-
Ribavirin monotherapy in patients with chronic hepatitis C: A retrospective study of 95 patients
-
Zoulim F, Haem J, Ahmed SS et al: Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Viral Hepat, 1998; 5: 193-98
-
(1998)
J Viral Hepat
, vol.5
, pp. 193-198
-
-
Zoulim, F.1
Haem, J.2
Ahmed, S.S.3
-
31
-
-
10344259671
-
Ribavirin treatment for patients with chronic hepatitis C: Result of a placebo-controlled study
-
Dusheiko G, Main J, Thomas H et al: Ribavirin treatment for patients with chronic hepatitis C: result of a placebo-controlled study. J Hepatol, 1996; 25: 591-98
-
(1996)
J Hepatol
, vol.25
, pp. 591-598
-
-
Dusheiko, G.1
Main, J.2
Thomas, H.3
-
32
-
-
1542377471
-
Antiviral action of ribavirin in chronic hepatitis C
-
Pawlotsky JM, Dahari H, Neumann AU et al: Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology, 2004; 126: 703-14
-
(2004)
Gastroenterology
, vol.126
, pp. 703-714
-
-
Pawlotsky, J.M.1
Dahari, H.2
Neumann, A.U.3
-
33
-
-
77950976387
-
Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: Viral kinetics and modeling
-
Rong L, Perelson AS: Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. Crit Rev Immunol, 2010; 30: 131-48
-
(2010)
Crit Rev Immunol
, vol.30
, pp. 131-148
-
-
Rong, L.1
Perelson, A.S.2
-
34
-
-
0037251550
-
Peginterferon a2a (40 kD) plus ribavirin: A review of its use in the management of chronic hepatitis C
-
Keating G, Curran M: Peginterferon a2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs, 2003; 63: 701-30
-
(2003)
Drugs
, vol.63
, pp. 701-730
-
-
Keating, G.1
Curran, M.2
-
35
-
-
0036750664
-
Pegylated interferons for the treatment of chronic hepatitis C infection
-
Luxon BA, Grace M, Brassard D, Bordens R: Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther, 2002; 24: 1363-83
-
(2002)
Clin Ther
, vol.24
, pp. 1363-1383
-
-
Luxon, B.A.1
Grace, M.2
Brassard, D.3
Bordens, R.4
-
36
-
-
35549000195
-
Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia
-
Akuta N, Suzuki F, Kawamura Y et al: Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology, 2007; 50: 361-68
-
(2007)
Intervirology
, vol.50
, pp. 361-368
-
-
Akuta, N.1
Suzuki, F.2
Kawamura, Y.3
-
37
-
-
70349548852
-
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
-
Suppiah V, Moldovan M, Ahlenstiel G, et al: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet, 2009; 41: 1100-4
-
(2009)
Nat Genet
, vol.41
, pp. 1100-1104
-
-
Suppiah, V.1
Moldovan, M.2
Ahlenstiel, G.3
-
38
-
-
70349533037
-
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
-
Tanaka Y, Nishida N, Sugiyama M et al: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet, 2009; 41: 1105-9
-
(2009)
Nat Genet
, vol.41
, pp. 1105-1109
-
-
Tanaka, Y.1
Nishida, N.2
Sugiyama, M.3
-
39
-
-
70349292099
-
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
-
Ge D, Fellay J, Thompson AJ et al: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009; 461: 399-401
-
(2009)
Nature
, vol.461
, pp. 399-401
-
-
Ge, D.1
Fellay, J.2
Thompson, A.J.3
|